Effects of Periodontal‐Specific Exosomes and rhBMP2 on Osteogenic Behaviour and Differentiation of BMSCs
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Paras Ahmad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Biology, Rutgers School of Dental Medicine, The State University of New Jersey, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Exosomes, Bone Marrow Cells, Bone Morphogenetic Protein 2, Osteogenesis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Miron Research and Development in Dentistry.
Abstract (Originalsprache)
Growth factors, including recombinant human bone morphogenetic protein‐2 (rhBMP2), have been clinically utilised for large bone augmentation with good outcomes. Nevertheless, long‐term healing, swelling, safety concerns, and high cost limit their use. Exosomes, nanoscale extracellular vesicles, have emerged as promising regenerative alternatives. This study assessed the osteogenic potential of periodontal‐specific exosomes (Px) on bone marrow mesenchymal stem cells (BMSCs) compared to rhBMP2. Px were morphologically characterised by TEM and quantified via BCA assay. BMSCs were treated with Px at 1:10, 1:50, and 1:100 dilutions (100, 20, and 10 μg/mL) and compared to rhBMP2 (100 ng/mL). Px uptake was evaluated using PKH26 labeling. Functional assays included viability, migration, alkaline phosphatase (ALP) activity, alizarin red (ARS) mineralization, collagen, osteocalcin secretion, and RT‐PCR analysis of osteogenic genes. Px exhibited spheroidal to cup‐shaped morphology and internalisation in BMSCs up to 18 days. Compared to rhBMP2, Px promoted viability (1.14‐fold), migration (1.78‐fold) up to 1.14 and 1.78‐fold, ALP (1.48‐, 4.11‐fold), ARS (1.43‐, 14.71‐fold), collagen (1.40‐, 3.58‐fold), and osteocalcin (1.86‐, 5.2‐fold). Gene expression demonstrated significant upregulation of ALP (1.73‐fold), RUNX2 (1.70‐fold), OCN (1.36‐fold), and OPN (1.35‐fold). Overall, Px significantly enhanced BMSC osteogenesis compared to rhBMP2, highlighting their potential as a cell‐free nanotherapeutic in bone tissue engineering.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Biology, Rutgers School of Dental Medicine, The State University of New Jersey, Newark, New Jersey, USA.
- Clinical Research Center, Rutgers School of Dental Medicine, The State University of New Jersey, Newark, New Jersey, USA.
- Department of Research, Advanced PRF Education, Jupiter, Florida, USA.
- Department of Biological Sciences, Rutgers University, Newark, New Jersey, USA.
- Department of Periodontology, University of Bern, Bern, Switzerland.
- Department of Periodontology, Lake Erie College of Osteopathic Medicine School of Dental Medicine, Bradenton, Florida, USA.
ORCID-Profile: Paras Ahmad, Danyal A Siddiqui, Nima Farshidfar, Nathan Estrin, Richard J Miron
Förderung
- Miron Research and Development in Dentistry
Zitieren
APA
Ahmad, P., Siddiqui, D. A., Bianchi-Smak, J., Farshidfar, N., Estrin, N., Miron, R. J., & Kotsakis, G. A. (2026). Effects of Periodontal‐Specific Exosomes and rhBMP2 on Osteogenic Behaviour and Differentiation of BMSCs. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71039
Vancouver
Ahmad P, Siddiqui DA, Bianchi-Smak J, Farshidfar N, Estrin N, Miron RJ, et al. Effects of Periodontal‐Specific Exosomes and rhBMP2 on Osteogenic Behaviour and Differentiation of BMSCs. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71039
BibTeX
@article{Ahmad2026,
author = {Ahmad, Paras and Siddiqui, Danyal A and Bianchi-Smak, Jared and Farshidfar, Nima and Estrin, Nathan and Miron, Richard J and Kotsakis, Georgios A},
title = {Effects of Periodontal‐Specific Exosomes and rhBMP2 on Osteogenic Behaviour and Differentiation of BMSCs},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71039}
}
EUVIMED